ValuEngine lowered shares of Fresenius Medical Care AG & Co. (NYSE:FMS) from a hold rating to a sell rating in a research note issued to investors on Wednesday, October 17th.

Several other equities analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Fresenius Medical Care AG & Co. from a hold rating to a sell rating in a report on Friday, August 3rd. Royal Bank of Canada reiterated a neutral rating on shares of Fresenius Medical Care AG & Co. in a report on Friday, August 17th. Bank of America started coverage on shares of Fresenius Medical Care AG & Co. in a report on Monday, July 9th. They issued a buy rating on the stock. HSBC upgraded shares of Fresenius Medical Care AG & Co. from a hold rating to a buy rating in a report on Tuesday, August 28th. Finally, DZ Bank reiterated a buy rating on shares of Fresenius Medical Care AG & Co. in a report on Monday, August 6th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $67.33.

Get Fresenius Medical Care AG & Co. alerts:

FMS traded down $1.28 during trading on Wednesday, reaching $40.07. 477,012 shares of the stock were exchanged, compared to its average volume of 322,843. The company has a market cap of $26.46 billion, a price-to-earnings ratio of 18.13, a PEG ratio of 1.91 and a beta of 1.10. Fresenius Medical Care AG & Co. has a twelve month low of $38.43 and a twelve month high of $57.94. The company has a current ratio of 1.24, a quick ratio of 1.00 and a debt-to-equity ratio of 0.41.

Several large investors have recently added to or reduced their stakes in the business. Sustainable Insight Capital Management LLC bought a new stake in shares of Fresenius Medical Care AG & Co. in the third quarter valued at about $243,000. Crossmark Global Holdings Inc. boosted its position in shares of Fresenius Medical Care AG & Co. by 11.0% in the third quarter. Crossmark Global Holdings Inc. now owns 56,248 shares of the company’s stock valued at $2,892,000 after acquiring an additional 5,582 shares during the period. MML Investors Services LLC bought a new stake in shares of Fresenius Medical Care AG & Co. in the third quarter valued at about $256,000. Rhumbline Advisers bought a new stake in shares of Fresenius Medical Care AG & Co. in the third quarter valued at about $263,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Fresenius Medical Care AG & Co. by 3.4% in the third quarter. JPMorgan Chase & Co. now owns 87,216 shares of the company’s stock valued at $4,484,000 after acquiring an additional 2,854 shares during the period. Hedge funds and other institutional investors own 2.46% of the company’s stock.